Country: Malta
Language: English
Source: Medicines Authority
ENTACAPONE
Pinewood Laboratories Limited Ballymacarbry, Clonmel, Co. Tipperary, Ireland
N04BX02
ENTACAPONE 200 mg
FILM-COATED TABLET
ENTACAPONE 200 mg
POM
ANTI-PARKINSON DRUGS
Withdrawn
2012-04-12
Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ENTACAPONE 200 MG FILM-COATED TABLETS Entacapone (Referred to as Entacapone Tablets in the remainder of the leaflet) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor, pharmacist or nurse. − This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. − If you get any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Entacapone Tablets are and what they are used for 2. What you need to know before you take Entacapone Tablets 3. How to take Entacapone Tablets 4. Possible side effects 5. How to store Entacapone Tablets 6. Contents of the pack and other information 1. WHAT ENTACAPONE TABLETS ARE AND WHAT THEY ARE USED FOR 1. WHAT ENTACAPONE TABLETS ARE AND WHAT THEY ARE USED FOR Entacapone Tablets contain entacapone and are used together with levodopa to treat Parkinson’s disease. Entacapone Tablets aids levodopa in relieving the symptoms of Parkinson's disease. Entacapone Tablets has no effect on relieving the symptoms of Parkinson´s disease unless taken with levodopa. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTACAPONE TABLETS 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTACAPONE TABLETS DO NOT TAKE ENTACAPONE TABLETS • if you are allergic to entacapone or any of the other ingredients of this medicine (listed in Section 6); • if you have a tumour of the adrenal gland (known as pheochromocytoma; this may increase the risk of severe high blood pressure); • if you are taking certain antidepressants (ask your doctor or pharmacist whether your antidepressive medicine can be taken together with Entacapone Tablets); • if you have liver disease; • if you have ever suffered Read the complete document
Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Entacapone 200 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 200mg entacapone. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Brownish-orange, oval, biconvex film-coated tablet with “W477” engraved on one side and plain on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in adult patients with Parkinson’s disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Entacapone should only be used in combination with levodopa/benserazide or levodopa/carbidopa. The prescribing information for these levodopa preparations is applicable to their concomitant use with entacapone. Posology One 200 mg tablet is taken with each levodopa/dopa decarboxylase inhibitor dose. The maximum recommended dose is 200 mg ten times daily, i.e. 2,000 mg of entacapone. Entacapone enhances the effects of levodopa. Hence, to reduce levodopa-related dopaminergic adverse reactions, e.g. dyskinesias, nausea, vomiting and hallucinations, it is often necessary to adjust levodopa dosage within the first days to first weeks after initiating entacapone treatment. The daily dose of levodopa should be reduced by about 10-30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. If entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations slightly (5-10%) more than from standard levodopa/carbidopa preparations. Page 2 of 10 Hence, patients w Read the complete document